Kerschbaum H, Moritz A J
Padiatr Padol. 1983;18(4):403-8.
Josamycin, one of the more recent macrolide antibiotics, was evaluated in 29 children aged from 2 months to 13 years with bronchopulmonary or otorhinological disease. With a daily dose in the range 30 to 60 mg/kg bodyweight, and an average treatment period of 7.7 days, 24 children were cured and 5 markedly improved. In only 4 children were minor side effects, such as gastrointestinal disturbances, observed, which in no case necessitated interruption of therapy. By virtue of its spectrum of activity josamycin seems to be an ideal antibiotic for the treatment of bacterial respiratory tract infections. In addition, josamycin displays a high degree of activity against mycoplasmas and chlamydiae. Only a very low percentage, reported as 6%, of staphylococcal are primarily resistant to the antibiotic, and the rapid development of resistance to other macrolides, has not been reported for josamycin. No cross resistance exists between josamycin and penicillins, cephalosporins, tetracycline or aminoglycosides. These characteristics represents josamycin for the treatment of respiratory tract infections. The pleasant taste of the preparation used in this study ensured its ready acceptance by the children treated.
交沙霉素是一种较新的大环内酯类抗生素，对29名年龄在2个月至13岁之间患有支气管肺部或耳鼻喉疾病的儿童进行了评估。每日剂量为30至60毫克/千克体重，平均治疗期为7.7天，24名儿童治愈，5名明显好转。仅4名儿童出现轻微副作用，如胃肠道不适，但无一例需要中断治疗。凭借其活性谱，交沙霉素似乎是治疗细菌性呼吸道感染的理想抗生素。此外，交沙霉素对支原体和衣原体具有高度活性。据报道，只有极低比例（6%）的葡萄球菌对该抗生素主要耐药，且尚未有交沙霉素对其他大环内酯类药物迅速产生耐药性的报道。交沙霉素与青霉素、头孢菌素、四环素或氨基糖苷类之间不存在交叉耐药性。这些特性表明交沙霉素可用于治疗呼吸道感染。本研究中使用的制剂味道宜人，确保了接受治疗的儿童易于接受。
